Low Levels of Serum Ferritin Lead to Adequate Hemoglobin Levels and Good Survival in Hemodialysis Patients

American Journal of Nephrology

Volumn 40, Issue 6, 2015, Pages 561-570

  Ogawa, Chie ^a,c   Tsuchiya, Ken ^b,c   Kanda, Fumiyoshi ^a,c   Maeda, Teiryo ^a,c  

^a Maeda Institute of Renal Research   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Biomarker Society INC   (Japan)

Author keywords

Anemia; Hemodialysis; Mortality; Serum ferritin

Indexed keywords

ANTIANEMIC AGENT; FERRITIN; HEMOGLOBIN; TRANSFERRIN; IRON;

ADULT; ANEMIA; ARTICLE; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; SURVIVAL; SURVIVAL RATE; ADVERSE EFFECTS; AGED; BLOOD; CAUSE OF DEATH; DIET SUPPLEMENTATION; METABOLISM; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY;

ADULT; AGED; ANEMIA; CAUSE OF DEATH; DIETARY SUPPLEMENTS; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSFERRIN;

EID: 84923619058     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000370317     Document Type: Article

References (43)

1. Pisoni RL, Bragg-Gresham JL, Young EW, et al: Anemia management and outcomes from
2. countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 94-111.
3. Tsubakihara Y, Nishi S, Akiba T, et al: 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010; 14: 240-275.
4. Ali MA, Luxton AW, Walker WH: Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J 1978; 118: 945-946.
5. Punnonen K, Irjala K, Rajamaki A: Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89: 1052-1057.
6. Mast AE, Blinder MA, Gronowski AM, et al: Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998; 44: 45-51.
7. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78.
8. Reis KA, Guz G, Ozdemir H, et al: Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 2005; 46: 255-264.
9. Kiechl S, Willeit J, Egger G, et al: Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. Circulation 1997; 96: 3300-3307.
10. Drueke T, Witko-Sarsat V, Massy Z, et al: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217.
11. Klipstein-Grobusch K, Koster JF, Grobbee DE, et al: Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr 1999; 69: 1231-1236.
12. Brookhart MA, Freburger JK, Ellis AR, et al: Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158.
13. Sengoelge G, Sunder-Plassmann G, Horl WH: Potential risk for infection and atherosclerosis due to iron therapy. J Ren Nutr 2005; 15: 105-110.
14. Kato J, Miyanishi K, Kobune M, Nakamura T, et al: Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007; 42: 830-836.
15. Kobayashi H, Yamada Y, Kanayama S, et al: The role of iron in the pathogenesis of endometriosis. Gynecol Endcrinol 2009; 25: 39-52.
16. Roob JM, Khoschsorur G, Tiran A, et al: Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549.
17. Anraku M, Kitamura K, Shintomo R, et al: Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study. Clin Biochem 2008; 41: 1168-1174
18. Park CH, Valore EV, Waring AJ, et al: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-7810.
19. Ganz T: Hepcidin-a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 2006; 108: 1381-1387.
20. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(suppl 3):S58-S70.
21. Lacatelli F, Covic A, Eckardt KU, et al: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice. Nephrol Dial Transplant 2009; 24: 348-354.
22. Otaki Y, Nakanishi T, Hasuike Y, et al: Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis 2004; 43: 1030-1039.
23. Patruta SI, Edlinger R, Sunder-Plassmann G, et al: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-663.
24. Skikne BS, Cook JD: Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med 1992; 120: 746-751.
25. Major A, Mathez-Loic F, Rohling R, et al: The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol 1997; 98: 292-294.
26. Wish JB: Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol 2006; 1(suppl 1):S4-S8.
27. Goodnough LT, Nemeth E, Ganz T: Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116: 4754-4761.
28. Pasricha SR, Flecknoe-Brown SC, Allen KJ, et al: Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 2010; 193: 525-532.
29. Koo HM, Kim CH, Doh FM, et al: The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS One 2014; 9:e87231.
30. Worwood M: Ferritin. Blood Rev 1990; 4: 259-269.
31. Jankowska EA, von Haehling S, Anker SD, et al: Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816-829.
32. Pagani A, Nai A, Corna G, et al: Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood 2011; 118: 736-746.
33. Noto JM, Gaddy JA, Lee JY, et al: Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. J Clin Invest 2013; 123: 479-492.
34. Jian J, Yang Q, Shao Y, et al: A link between premenopausal iron deficiency and breast cancer malignancy. BMC Cancer 2013; 13: 307.
35. Bailie GR, Larkina M, Goodkin DA, et al: Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2013; 28: 2570-2579.
36. Canavese C, Bergamo D, Ciccone G, et al: Validation of serum ferritin values by magnetic susceptometory in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098.
37. Rostoker G, Griuncelli M, Loridon C, et al: Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012; 125: 991-999.
38. Van Buren P, Velez RL, Vaziri ND, et al: Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012; 44: 499-507.
39. Hasuike Y, Nonoguchi H, Tokuyama M, et al: Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol 2010; 14: 349-355.
40. Kuragano T, Matsumura O, Matsuda A, et al: Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int 2014; 86: 845-854.
41. Akizawa T, Pisoni RL, Akiba T, et al: Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dial Transplant 2008; 23: 3643-3653.
42. Tomosugi N, Kawabata H, Wakatabe R, et al: Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: 1381-1387.
43. Gejyo F, Saito A, Akizawa T, et al; Japanese Society for Dialysis Therapy: 2004 Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004; 8: 443-459.